With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of ...
Artivion (NYSE:AORT) this week announced it received FDA humanitarian device exemption (HDE) for its AMDS Hybrid Prosthesis.
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting ...
Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.
Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.
A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...
Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 ...
Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who were treated with revumenib, with no new safety signals found.